These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 24780410

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
    Rolland Y, Abellan Van Kan G, Gillette-Guyonnet S, Roux C, Boonen S, Vellas B.
    Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
    [Abstract] [Full Text] [Related]

  • 4. Generalized cutaneous drug eruption due to strontium ranelate.
    Boada A, Carrascosa JM, Leal L, Ferrándiz C.
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):321-2. PubMed ID: 18624862
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Strontium ranelate: new perspectives for the management of osteoporosis.
    Cortet B.
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv1-2. PubMed ID: 19783588
    [No Abstract] [Full Text] [Related]

  • 10. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S.
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [Abstract] [Full Text] [Related]

  • 11. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
    Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY.
    Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Osteoporosis in the man: broad indication for strontium ranelate].
    MMW Fortschr Med; 2012 Nov 29; 154(21):86-7. PubMed ID: 23270063
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Strontium ranelate: a look back at its use for osteoporosis.
    Reginster JY, Neuprez A.
    Expert Opin Pharmacother; 2010 Dec 29; 11(17):2915-27. PubMed ID: 21050035
    [Abstract] [Full Text] [Related]

  • 19. [Strontium ranelate (Osseor)--unique double mechanism--physiologic bone treatment as live tissue].
    Novak S.
    Reumatizam; 2007 Dec 29; 54(2):83-4. PubMed ID: 18351151
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
    Namazi H.
    Curr Med Res Opin; 2012 Apr 29; 28(4):609; author reply 609-10. PubMed ID: 22435797
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.